6th Oct 2020 14:19
(Alliance News) - Oxford BioMedica PLC on Tuesday reported promising results from follow-up data of a Parkinson's disease medication which the gene and cell therapy firm out-licenced back in 2018.
The FTSE 250-listed company noted an announcement from Axovant Gene Therapies which said that the AXO-Lenti-PD gene therapy was well-tolerated and had no serious adverse events during a six-month follow up.
Axovant also noted a "40% improvement from baseline based on the two evaluable patients in the study, exceeding predefined criteria for success".
Back in June 2018, Oxford BioMedica out-licenced AXO-Lenti-PD, or OXB-102 as it was labelled back then, to Axovant as part of a USD842.5 million agreement.
"In July 2020 a three year clinical supply agreement was additionally signed with Axovant to manufacture GMP batches to support the ongoing and future clinical development of AXO-Lenti-PD," Oxford BioMedica added.
Shares in the company were 1.0% higher at 853.44 pence each in London on Tuesday afternoon.
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica